* Note: Prices are in Million (M) USD.
Description:
Aura Biosciences Inc is an innovative clinical-stage biotechnology firm dedicated to revolutionizing cancer treatment through its proprietary virus-like particle (VLP) technology. The company's flagship investigational drug, AU-011, specifically targets ocular cancer cells, aiming to eradicate malignancies while preserving healthy tissue—a testament to its advancements in precision oncology. With a comprehensive clinical pipeline addressing significant unmet needs in cancer care and a seasoned management team at the helm, Aura is well-positioned for impactful contributions to the oncology landscape. Additionally, its strategic collaborations enhance its capacity for innovation, aligning with the evolving demand for targeted therapies within the healthcare sector.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $0 M
Debt : $0 M
EBITDA : $0 M
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Error: Invalid cash flow data provided.Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used company's growth potential to calculate its fair value:
Error: Invalid income data provided.Using default values for calculation.
This criteria used Company's ability to buy back its own share:
Error: Invalid balance sheet data provided.Using default values for calculation.
Based on default values, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.00
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Error: Invalid income data provided.Skipping ROE-based PE.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $7.03
52-Week Low: $4.73
Threshold Price (15% Above 52-Week Low): $5.44
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $718 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 8 points to above Aura Biosciences Inc (AURA) stock.
Fair Value PE 9, Industry Based PE 15, Risk-Free Anchored PE (25% MoS) 16.78. Based on these 3 values, average assigned is 13.59. The fair value of Aura Biosciences Inc (AURA) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
